Indo Us Bio-Tech Limited

NSEI:INDOUS Stock Report

Market Cap: ₹5.8b

Indo Us Bio-Tech Management

Management criteria checks 4/4

Indo Us Bio-Tech's CEO is Jagdishkumar Ajudia, appointed in Nov 2017, has a tenure of 7.08 years. directly owns 54.55% of the company’s shares, worth ₹3.16B. The average tenure of the management team and the board of directors is 7 years and 6.3 years respectively.

Key information

Jagdishkumar Ajudia

Chief executive officer

₹1.3m

Total compensation

CEO salary percentagen/a
CEO tenure7.1yrs
CEO ownership54.6%
Management average tenure7yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Optimistic Investors Push Indo Us Bio-Tech Limited (NSE:INDOUS) Shares Up 37% But Growth Is Lacking

Dec 10
Optimistic Investors Push Indo Us Bio-Tech Limited (NSE:INDOUS) Shares Up 37% But Growth Is Lacking

There's Reason For Concern Over Indo Us Bio-Tech Limited's (NSE:INDOUS) Price

Oct 09
There's Reason For Concern Over Indo Us Bio-Tech Limited's (NSE:INDOUS) Price

CEO Compensation Analysis

How has Jagdishkumar Ajudia's remuneration changed compared to Indo Us Bio-Tech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹117m

Jun 30 2024n/an/a

₹90m

Mar 31 2024₹1mn/a

₹83m

Dec 31 2023n/an/a

₹105m

Sep 30 2023n/an/a

₹82m

Jun 30 2023n/an/a

₹81m

Mar 31 2023₹1mn/a

₹72m

Dec 31 2022n/an/a

₹58m

Sep 30 2022n/an/a

₹57m

Jun 30 2022n/an/a

₹54m

Mar 31 2022₹1m₹1m

₹51m

Dec 31 2021n/an/a

₹55m

Sep 30 2021n/an/a

₹59m

Jun 30 2021n/an/a

₹54m

Mar 31 2021₹1m₹1m

₹49m

Dec 31 2020n/an/a

₹39m

Sep 30 2020n/an/a

₹28m

Jun 30 2020n/an/a

₹27m

Mar 31 2020₹1m₹1m

₹25m

Dec 31 2019n/an/a

₹24m

Sep 30 2019n/an/a

₹22m

Jun 30 2019n/an/a

₹22m

Mar 31 2019₹2m₹2m

₹21m

Mar 31 2018₹1m₹1m

₹14m

Compensation vs Market: Jagdishkumar's total compensation ($USD15.23K) is below average for companies of similar size in the Indian market ($USD42.37K).

Compensation vs Earnings: Jagdishkumar's compensation has been consistent with company performance over the past year.

CEO

Jagdishkumar Ajudia (54 yo)

7.1yrs

Tenure

₹1,296,000

Compensation

Mr. Jagdishkumar Devjibhai Ajudia is a Promoter and has been Managing Director & Chairman of Indo Us Bio-Tech Ltd since November 23, 2017 and its Executive & Non Independent Director since February 04, 200...

Leadership Team

NamePositionTenureCompensationOwnership
Jagdishkumar Ajudia
Chairman & MD7.1yrs₹1.30m54.55%
₹ 3.2b
Rinku Jethva
Chief Finance Officer6.9yrs₹318.46kno data
Dimpy Joshi
Company Secretary & Compliance Officer4.9yrs₹315.30kno data
Priyanka Ajudia
Executive & Non-Independent Directorno data₹600.01k1.99%
₹ 115.4m
Maltiben Ajudia
Whole Time Directorno data₹621.52k2.91%
₹ 168.5m
Balvantbhai Baraiya
Head of Marketingno datano datano data
Falguni Oza
Head of Human Resources7.7yrsno datano data

7.0yrs

Average Tenure

38.5yo

Average Age

Experienced Management: INDOUS's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jagdishkumar Ajudia
Chairman & MD20.8yrs₹1.30m54.55%
₹ 3.2b
Priyanka Ajudia
Executive & Non-Independent Director7.1yrs₹600.01k1.99%
₹ 115.4m
Maltiben Ajudia
Whole Time Director6.9yrs₹621.52k2.91%
₹ 168.5m
Ritaben Kikani
Non-Executive Independent Director5.8yrs₹30.00kno data
Nehaben Patel
Non-Executive Independent Director3.3yrsno datano data
Shilpa Thumar
Non-Executive Independent Director3.3yrsno datano data

6.3yrs

Average Tenure

45.5yo

Average Age

Experienced Board: INDOUS's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 21:11
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Indo Us Bio-Tech Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution